RxDoctor Payments Data

Justin Brown, MD

Family Medicine · Akron, OHNPI 1023691409

Payments from drug & device makers

$1,221in general payments, 2019–2025

Across 35 payments — averaging $34.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$330
  • Tulavi Therapeutics, Inc.$299
  • Indivior Inc.$125
  • Exact Sciences$117
  • AstraZeneca$80
  • Xeris Pharmaceuticals, Inc.$45
  • plus $225 from 10 others

What the payments were for

  • Food & beverage$1,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,221 in reported general payments places this provider in the 65th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$7,895
Medicare patients
33
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide58$57,693
FarxigaDapagliflozin Propanediol52$37,519
EliquisApixaban58$27,629
JardianceEmpagliflozin13$13,321
OzempicSemaglutide15$12,622
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,579
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$6,218
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,945
Varenicline Tartrate13$1,880
Atorvastatin Calcium131$1,207
Gabapentin69$960
Albuterol Sulfate HfaAlbuterol Sulfate40$938
Famotidine44$907
Rosuvastatin Calcium50$854
Fluticasone Propionate57$842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$16$57,69358 claims
AstraZenecaFarxiga$80$37,51952 claims
PfizerEliquis$19$27,62958 claims
GSKTrelegy Ellipta$15$9,57914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →